Safety, Tolerability and Pharmacokinetics of AZD1775 (adavosertib) plus MEDI4736 (durvalumab) in Patients with Advanced Solid Tumours

Study identifier:D6015C00002

ClinicalTrials.gov identifier:NCT02617277

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (adavosertib) in Combination with MEDI4736 (durvalumab) in Patients with Advanced Solid Tumours

Medical condition

Advanced Solid Tumours

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1775, MEDI4736

Sex

All

Actual Enrollment

56

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 28 Dec 2015
Primary Completion Date: 22 Apr 2019
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria